Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nutriband Inc. - Warrant (NQ:NTRBW)

2.270 UNCHANGED
Streaming Delayed Price Updated: 3:55 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nutriband Inc. - Warrant

< Previous 1 2 3 4 Next >
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
Via ACCESSWIRE
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
Via ACCESSWIRE
Nutriband CEO Publishes Letter to Shareholders
Via ACCESSWIRE
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
Via ACCESSWIRE
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
Via ACCESSWIRE
Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023
Via ACCESSWIRE
Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador
Via ACCESSWIRE
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
Via ACCESSWIRE
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
Via ACCESSWIRE
Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
Via ACCESSWIRE
Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
ORLANDO, FL / September 20, 2023 (PlatoData via 500NewsWire) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance... 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission
Via ACCESSWIRE
Nutriband Inc. Commences Trading on Upstream Under NTRB
Via ACCESSWIRE
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology Orlando, FL – September 20, 2023 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Inc. Will Be the First Company to Dual List on Upstream
Via ACCESSWIRE
Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
Via ACCESSWIRE
Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings
ORLANDO, FL / PlatoData via 500NewsWire / July 27, 2023 / Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of... 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings
Via ACCESSWIRE
Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology
Via ACCESSWIRE
Nutriband to Attend 2023 BIO International Convention
Via ACCESSWIRE
Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023
Via ACCESSWIRE
Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023
Via ACCESSWIRE
Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development
Via ACCESSWIRE
Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology
Via ACCESSWIRE
Nutriband Inc Joins Webull Corporate Communications Service Platform
Via ACCESSWIRE
Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert Committee
Via ACCESSWIRE
Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health Register
Via ACCESSWIRE
Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.